Ann Surg Treat Res.  2018 Apr;94(4):183-189. 10.4174/astr.2018.94.4.183.

Prognosis of preoperative positron emission tomography uptake in hepatectomy patients

Affiliations
  • 1Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jw.joh@samsung.com
  • 2Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

PURPOSE
Preoperative F-18-fluoro-2-deoxy-glucose positron emission tomography (18F-FDG PET) imaging results appear to predict tumor recurrence and patient survival. The present study compared outcomes between PET-positive and PET-negative groups with HBV-related hepatocellular carcinoma (HCC) who underwent curative hepatectomy and assessed the prognostic value of positive PET-CT for HCC recurrence and death.
METHODS
This study included patients who underwent liver resection of solitary HCC between 2007 and 2014 based on preoperative radiological images. There were 133 patients in the PET-positive group and 93 in the PET-negative group.
RESULTS
There were no statistically significant differences in baseline, perioperative, or pathologic characteristics between the 2 groups except HBsAg titer, tumor size, and presence of bile duct tumor thrombi. Multivariate analysis showed that tumor size >3.5 cm and HBsAg titer >1,000 cutoff index were predisposing factors of positive PET-CT. Disease-free survival and overall survival rate at 1, 3, and 5 years were 76.3%, 64.4%, 60.3% and 96.8%, 91.1%, 85.1% in the PET-negative group, respectively, compared with 70.7%, 62.2%, 58.9% and 98.5%, 97.0%, 97.0% in the PET-positive group (P = 0.547 and P = 0.046). Multivariate analysis showed that positive PET-CT was closely associated with increased patient survival, but was not related to HCC recurrence.
CONCLUSION
These results suggest that positive PET findings are not a predisposing factor for recurrence of HBV-related HCC patients, but appear to be associated with improved patient survival. Further prospective studies are needed to confirm the prognostic value of 18F-FDG PET in these patients.

Keyword

Hepatocellular carcinoma; Hepatitis B virus; Outcome

MeSH Terms

Bile Ducts
Carcinoma, Hepatocellular
Causality
Disease-Free Survival
Electrons*
Fluorodeoxyglucose F18
Hepatectomy*
Hepatitis B Surface Antigens
Hepatitis B virus
Humans
Liver
Multivariate Analysis
Positron-Emission Tomography*
Prognosis*
Prospective Studies
Recurrence
Survival Rate
Fluorodeoxyglucose F18
Hepatitis B Surface Antigens

Figure

  • Fig. 1 Disease-free survival.

  • Fig. 2 Overall survival.


Cited by  1 articles

Validation for models for tumor recurrence after liver transplantation in hepatectomy patients
Sung Joon Kim, Jong Man Kim, Nam-Joon Yi, Gyu-Seong Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh
Ann Surg Treat Res. 2022;102(3):131-138.    doi: 10.4174/astr.2022.102.3.131.


Reference

1. Kim JM, Kwon CH, Joh JW, Park JB, Ko JS, Lee JH, et al. The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma. World J Surg Oncol. 2013; 11:40.
Article
2. Kim JM, Kwon CH, Joh JW, Ko JS, Park JB, Lee JH, et al. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol. 2013; 11:92.
Article
3. Kim JM, Hyuck C, Kwon D, Joh JW, Lee JH, Paik SW, et al. Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma. World J Surg. 2013; 37:1371–1378.
Article
4. Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, et al. Differences between hepatocellular carcinoma and hepatitis B virus infection in patients with and without cirrhosis. Ann Surg Oncol. 2014; 21:458–465.
Article
5. Asman Y, Evenson AR, Even-Sapir E, Shibolet O. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and locoablative therapies for hepatocellular carcinoma. Liver Transpl. 2015; 21:572–580.
Article
6. Gauthe M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, et al. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis. 2015; 47:443–454.
7. Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, et al. Prognostic significance of 18F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy: a multicenter retrospective cohort study. J Nucl Med. 2016; 57:509–516.
Article
8. Chen YK, Hsieh DS, Liao CS, Bai CH, Su CT, Shen YY, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res. 2005; 25(6C):4719–4725.
9. Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol. 2007; 13:2775–2783.
Article
10. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007; 13(2 Pt 1):427–433.
Article
11. Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, et al. Outcomes after curative hepatectomy in patients with non-B non-C hepatocellular carcinoma and hepatitis B virus hepatocellular carcinoma from non-cirrhotic liver. J Surg Oncol. 2014; 110:976–981.
Article
12. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 2nd ed. Tokyo: Kanehara & Co.;2003.
13. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7:462–503.
14. Hyun SH, Eo JS, Lee JW, Choi JY, Lee KH, Na SJ, et al. Prognostic value of (18) F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging. 2016; 43:1638–1645.
15. Sun DW, An L, Wei F, Mu L, Shi XJ, Wang CL, et al. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a metaanalysis. Abdom Radiol (NY). 2016; 41:33–41.
Article
16. Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol. 2014; 49:46–56.
Article
17. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDGPET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl. 2006; 12:1655–1660.
18. Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009; 9:592–600.
Article
19. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003; 44:213–221.
20. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int. 2013; 33:Suppl 1. 125–132.
Article
21. Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with epatocellular carcinoma. J Hepatol. 2006; 45:553–559.
22. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol. 2001; 96:1877–1880.
Article
23. Pant V, Sen IB, Soin AS. Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun. 2013; 34:749–757.
24. Rohren EM, Paulson EK, Hagge R, Wong TZ, Killius J, Clavien PA, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med. 2002; 27:550–555.
Article
25. Hong G, Suh KS, Suh SW, Yoo T, Kim H, Park MS, et al. Alpha-fetoprotein and (18) F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016; 64:852–859.
26. Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within milan criteria undergoing liver transplantation: analysis of 3601 patients from the US multicenter HCC transplant consortium. Ann Surg. 2017; 266:525–535.
Full Text Links
  • ASTR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr